Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KNSA Stock 12 Month Forecast
Average Price Target
$50.67
▲(31.64% Upside)
| Highest Price Target$60.00 | Average Price Target$50.67 | Lowest Price Target$45.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
$60
Buy
55.88%
Upside
Initiated
09/29/25
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst's Market Success and Promising PipelineWe initiate at DCF-based PT. 93% Best-In-Indication Profile... Arcalyst is an IL-1 antagonist that treats the underlying disease pathology of recurrent pericarditis, which Kiniksa in-licensed from Regeneron in 2017. The impressive efficacy in the Phase III RHAPSODY trial is highlighted by the rapid pain relief by 5 days post a single treatment course and the unprecedented 93% (n=29/31) freedom from recurrence vs. 26% for placebo. This drove the impressive 96% risk reduction (HR=0.04) in median time to recurrence, which was not reached with Arcalyst at one-year vs 8.6 weeks for placebo. The only two patients to recur on Arcalyst were those that had a dose interruption, reinforcing the need for compliance to remain recurrence free.
Wells Fargo
$42→$45
Buy
16.91%
Upside
Reiterated
09/25/25
J.P. Morgan
$47→$55
Buy
42.89%
Upside
Reiterated
08/06/25
Citi
$40→$45
Buy
16.91%
Upside
Reiterated
07/30/25
Jefferies
$45→$54
Buy
40.30%
Upside
Reiterated
07/29/25
Evercore ISI
$35
Buy
-9.07%
Downside
Reiterated
05/12/25
Wedbush
$34
Buy
-11.67%
Downside
Reiterated
04/16/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
$60
Buy
55.88%
Upside
Initiated
09/29/25
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst's Market Success and Promising PipelineWe initiate at DCF-based PT. 93% Best-In-Indication Profile... Arcalyst is an IL-1 antagonist that treats the underlying disease pathology of recurrent pericarditis, which Kiniksa in-licensed from Regeneron in 2017. The impressive efficacy in the Phase III RHAPSODY trial is highlighted by the rapid pain relief by 5 days post a single treatment course and the unprecedented 93% (n=29/31) freedom from recurrence vs. 26% for placebo. This drove the impressive 96% risk reduction (HR=0.04) in median time to recurrence, which was not reached with Arcalyst at one-year vs 8.6 weeks for placebo. The only two patients to recur on Arcalyst were those that had a dose interruption, reinforcing the need for compliance to remain recurrence free.
Wells Fargo
$42→$45
Buy
16.91%
Upside
Reiterated
09/25/25
J.P. Morgan
$47→$55
Buy
42.89%
Upside
Reiterated
08/06/25
Citi
$40→$45
Buy
16.91%
Upside
Reiterated
07/30/25
Jefferies
$45→$54
Buy
40.30%
Upside
Reiterated
07/29/25
Evercore ISI
$35
Buy
-9.07%
Downside
Reiterated
05/12/25
Wedbush
$34
Buy
-11.67%
Downside
Reiterated
04/16/25
Best Analysts Covering Kiniksa Pharmaceuticals
1 Month
xxx
Success Rate
9/19 ratings generated profit
Average Return
+3.31%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of +3.31% per trade.
3 Months
xxx
Success Rate
13/19 ratings generated profit
Average Return
+22.14%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +22.14% per trade.
1 Year
Success Rate
10/12 ratings generated profit
Average Return
+28.52%
reiterated a buy rating 2 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +28.52% per trade.
2 Years
xxx
Success Rate
16/17 ratings generated profit
Average Return
+58.04%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +58.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KNSA Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
6
5
2
2
3
Buy
2
7
12
11
8
Hold
3
2
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
14
14
13
11
Each month's total comprises the sum of three months' worth of ratings.
KNSA Financial Forecast
KNSA Stock Forecast FAQ
What is KNSA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kiniksa Pharmaceuticals’s 12-month average price target is 50.67.
What is KNSA’s upside potential, based on the analysts’ average price target?
Kiniksa Pharmaceuticals has 31.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KNSA a Buy, Sell or Hold?
Kiniksa Pharmaceuticals has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Kiniksa Pharmaceuticals’s price target?
The average price target for Kiniksa Pharmaceuticals is 50.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $45.00. The average price target represents 31.64% Increase from the current price of $38.49.
The highest analyst price target is $60.00 ,the lowest forecast is $45.00. The average price target represents 31.64% Increase from the current price of $38.49.
What do analysts say about Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of KNSA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.